How RecursiveMAS speeds up multi-agent inference by 2.4x and reduces token usage by 75%

UIUC and Stanford's RecursiveMAS lets AI agents collaborate in embedding space instead of text, cutting token usage by 75% ...
The Motley Fool

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...
CNBC

Recursion CEO Chris Gibson talks integrating AI into drug development process

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...
GEN

Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...